101 related articles for article (PubMed ID: 31177140)
1. Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies.
El Ali Z; Rottey S; Barthelemy P; Kotecki N; VAN Paemel R; Devrient D; Awada A; Gil T; Pannier D; Ryckewaert T; Waisse W; Clavier JB; Penel N; Vermassen T
Anticancer Res; 2019 Jun; 39(6):2993-3002. PubMed ID: 31177140
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Vickers MM; Al-Harbi H; Choueiri TK; Kollmannsberger C; North S; MacKenzie M; Knox JJ; Rini BI; Heng DY
Clin Genitourin Cancer; 2013 Sep; 11(3):311-5. PubMed ID: 23684422
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Rebibo JD; Pfister C; Giwerc A; Defortescu G; Gouerant S; Di Fiore F; Nouhaud FX
Prog Urol; 2016 Jan; 26(1):16-23. PubMed ID: 26455779
[TBL] [Abstract][Full Text] [Related]
4. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
[TBL] [Abstract][Full Text] [Related]
5. Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy.
Kang M; Park JY; Jeong CW; Hwang EC; Song C; Hong SH; Kwak C; Chung J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
J Urol; 2018 Nov; 200(5):989-995. PubMed ID: 29940249
[TBL] [Abstract][Full Text] [Related]
6. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
Nouhaud FX; Rebibo JD; Blanchard F; Sabourin JC; Di Fiore F; Pfister C
Prog Urol; 2014 Jul; 24(9):563-71. PubMed ID: 24975791
[TBL] [Abstract][Full Text] [Related]
8. Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice.
Thiery-Vuillemin A; Cholley T; Calcagno F; Hugues M; Maurina T; Limat S; Nguyen Tan Hon T; Almotlak H; Mouillet G; Nerich V
Clin Genitourin Cancer; 2018 Apr; 16(2):e297-e305. PubMed ID: 29066073
[TBL] [Abstract][Full Text] [Related]
9. Improving the Prognostic Value of Disease-Specific Graded Prognostic Assessment Model for Renal Cell Carcinoma by Incorporation of Cumulative Intracranial Tumor Volume.
Ali MA; Hirshman BR; Wilson B; Schupper AJ; Joshi R; Proudfoot JA; Goetsch SJ; Alksne JF; Ott K; Aiyama H; Nagano O; Carter BS; Chiang V; Serizawa T; Yamamoto M; Chen CC
World Neurosurg; 2017 Dec; 108():151-156. PubMed ID: 28754641
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment Prognostic Nutritional Index Is an Independent Predictor of Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapy.
Kwon WA; Kim S; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Clin Genitourin Cancer; 2017 Feb; 15(1):100-111. PubMed ID: 27601363
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium.
Fay AP; Xie WL; Lee JL; Harshman LC; Bjarnason GA; Knox JJ; Ernst S; Wood L; Vaishamayan UN; Yuasa T; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger CK; North SA; Rini BI; Choueiri TK; Heng DY
Clin Genitourin Cancer; 2015 Apr; 13(2):150-5. PubMed ID: 25458371
[TBL] [Abstract][Full Text] [Related]
13. Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score.
Le Scodan R; Massard C; Mouret-Fourme E; Guinebretierre JM; Cohen-Solal C; De Lalande B; Moisson P; Breton-Callu C; Gardner M; Goupil A; Renody N; Floiras JL; Labib A
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):839-45. PubMed ID: 17544592
[TBL] [Abstract][Full Text] [Related]
14. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy.
Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hoerner-Rieber J; König L; Kappes J; Thomas M; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
J Neurooncol; 2017 Aug; 134(1):205-212. PubMed ID: 28560661
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery.
Samlowski WE; Majer M; Boucher KM; Shrieve AF; Dechet C; Jensen RL; Shrieve DC
Cancer; 2008 Nov; 113(9):2539-48. PubMed ID: 18780316
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy.
Takamatsu K; Mizuno R; Omura M; Morita S; Matsumoto K; Shinoda K; Kosaka T; Takeda T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
Clin Genitourin Cancer; 2018 Aug; 16(4):e927-e933. PubMed ID: 29678472
[TBL] [Abstract][Full Text] [Related]
17. Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.
Li H; Lian J; Jin H; Wang W; Cao J; Zhang X; Song X; Jia S; Jia H; Ren J; Han S; Yang W; Xi Y; Lan S
J Neurooncol; 2017 May; 133(1):129-135. PubMed ID: 28391386
[TBL] [Abstract][Full Text] [Related]
18. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
19. Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Kawashima A; Tsujimura A; Takayama H; Arai Y; Nin M; Tanigawa G; Uemura M; Nakai Y; Nishimura K; Nonomura N;
Int J Urol; 2012 Dec; 19(12):1050-7. PubMed ID: 22860625
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era: The University of Rochester Experience.
Bates JE; Youn P; Peterson CR; Usuki KY; Walter KA; Okunieff P; Milano MT
Am J Clin Oncol; 2017 Oct; 40(5):439-443. PubMed ID: 25730604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
